Culture Change At GSK: 'We’re Doing What We Said We’d Do'
R&D Chief Says Doubters Are Coming Round
Executive Summary
Chief scientific offficer Hal Barron talks about winning hearts and minds of 10,000 R&D employees, and adopting practices from acquired company Tesaro.
You may also be interested in...
Hal Barron To Depart GSK To Head Up New Biotech
As Barron departs for new rejuvenation-focused biotech Altos Labs, GSK will be under pressure to ensure its R&D can continue to produce green shoots.
Deal Watch: GSK Furthers Cancer Gene Therapy Plans Via Lyell Collaboration
GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.
New Front Opens in First-Line Ovarian Cancer Market: GSK’s Zejula Vs. AZ’s Lynparza
Two new PARP inhibitor studies – GSK’s PRIMA and AstraZeneca/Merck & Co.’s PAOLA-1 – are set to widen the ovarian cancer market after they reported highly positive first-line results in advanced patients at ESMO.